Compare AKBA & KRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | KRO |
|---|---|---|
| Founded | 2007 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 604.0M |
| IPO Year | 2014 | N/A |
| Metric | AKBA | KRO |
|---|---|---|
| Price | $1.42 | $6.28 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 6 | 2 |
| Target Price | $5.92 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 3.1M | 321.5K |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 3.29% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $225,071,000.00 | ★ $1,864,200,000.00 |
| Revenue This Year | $52.41 | N/A |
| Revenue Next Year | $21.57 | $5.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.49 | 0.01 |
| 52 Week Low | $1.30 | $4.08 |
| 52 Week High | $4.08 | $9.85 |
| Indicator | AKBA | KRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 68.12 |
| Support Level | $1.35 | $5.72 |
| Resistance Level | $1.44 | $6.25 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 42.50 | 98.72 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.